Activation of nitric oxide synthase by β2‐adrenoceptors in human umbilical vein endothelium in vitro
- 1 April 1999
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 126 (8) , 1872-1880
- https://doi.org/10.1038/sj.bjp.0702512
Abstract
Some animal studies suggest that β‐adrenoceptor‐mediated vasorelaxation is in part mediated through nitric oxide (NO) release. Furthermore, in humans, we have recently shown that forearm blood flow is increased by infusion of β2‐adrenergic agonists into the brachial artery, and the nitric oxide synthase (NOS) inhibitor NG‐monomethyl‐L‐arginine (L‐NMMA) inhibits this response. The purpose of the present study was to determine whether stimulation of human umbilical vein endothelial β‐adrenoceptors causes vasorelaxation and nitric oxide generation, and whether this might be mediated by cyclic adenosine‐3′,5′‐monophosphate (cyclic AMP). Vasorelaxant responses were determined in umbilical vein rings to the nonselective β‐adrenergic agonist isoprenaline and to the cyclic AMP analogue dibutyryl cyclic AMP, following precontraction with prostaglandin F2α. NOS activity was measured in cultured human umbilical vein endothelial cells (HUVEC) by the conversion of [3H]‐L‐arginine to [3H]‐L‐citrulline, and adenylyl cyclase activity by the conversion of [α‐32P]‐ATP to [32P]‐cyclic AMP. Isoprenaline relaxed umbilical vein rings, and this vasorelaxation was abolished by β2‐ (but not β1‐) adrenergic blockage, and by endothelium removal or 1 mM L‐NMMA. In addition, vasorelaxant responses to dibutyryl cyclic AMP were inhibited by 1 mM L‐NMMA, with a reduction in Emax from 90.0±9.3% to 50.5±9.9% (PP2 (but not β1‐) adrenergic blockade. Forskolin 1 μM and dibutyryl cyclic AMP 1 mM each increased NOS activity in HUVEC, to a degree similar to isoprenaline 1 μM. The increase in L‐arginine to L‐citrulline conversion observed with each agent was abolished by co‐incubation with NOS inhibitors. These results indicate that endothelial β2‐adrenergic stimulation and cyclic AMP elevation activate the L‐arginine/NO system, and give rise to vasorelaxation, in human umbilical vein. British Journal of Pharmacology (1999) 126, 1872–1880; doi:10.1038/sj.bjp.0702512Keywords
This publication has 48 references indexed in Scilit:
- Coronary β-Adrenoceptor Function Is Modified by the Endothelium in Heart FailureJournal of Vascular Research, 1996
- Phorbol ester enhances activation of adenylate cyclase in Bovine aortic endothelial cellsLife Sciences, 1994
- Effect of NG-monomethyl-L-arginine on the β-adrenoceptor-mediated relaxation of rat mesenteric resistance arteriesLife Sciences, 1993
- Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cellsBiochemical and Biophysical Research Communications, 1990
- Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxationBiochemical and Biophysical Research Communications, 1989
- Biosynthesis of endothelium-derived relaxing factor: A cytosolic enzyme in porcine aortic endothelial cells Ca2+-dependently converts L-arginine into an activator of soluble guanylyl cyclaseBiochemical and Biophysical Research Communications, 1989
- A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cellsBiochemical and Biophysical Research Communications, 1989
- AUTORADIOGRAPHIC LOCALIZATION OF RECEPTORS IN THE MAMMALIAN CARDIOVASCULAR SYSTEMClinical and Experimental Pharmacology and Physiology, 1987
- Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta.Journal of Clinical Investigation, 1987
- Endothelium-Removal Decreases Relaxations of Canine Coronary Arteries Caused by β-Adrenergic Agonists and AdenosineJournal of Cardiovascular Pharmacology, 1985